Details

Autor(en) / Beteiligte

• Kraft, Walter K
• Adeniyi-Jones, Susan C
• Chervoneva, Inna
• Greenspan, Jay S
• Abatemarco, Diane
• Kaltenbach, Karol
• Ehrlich, Michelle E

Titel

Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome

Ist Teil von

• The New England journal of medicine, 2017-06, Vol.376 (24), p.2341-2348

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2017

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• In this single-center trial involving term infants with in utero opioid exposure, the use of sublingual buprenorphine resulted in a shorter duration of treatment and length of hospital stay than the use of oral morphine. The neonatal abstinence syndrome is defined as the occurrence of signs and symptoms of neonatal withdrawal after in utero drug exposure. 1 Among drug exposures, opioids cause severe symptoms, including autonomic instability, tremor, irritability, poor feeding, and loose stool. Measures that improve symptom control include minimization of stimulation, rooming in, 2 breast-feeding, 3 and frequent calorically dense feedings. Approximately two thirds of infants with this condition do not have a response to behavioral approaches and ultimately require pharmacologic therapy for control of symptoms. 4 The administration of an opioid at an appropriate dose for symptom control with subsequent weaning has been identified as an . . .